AZD8330 showed model-dependent effects in a six-line osteosarcoma panel. After 72 hours, ATP-associated viability decreased in MOS, U2OS and 143b, whereas KPD, ZK58 and Saos-2 were described as unaffected over the tested concentration series. The responsive lines had higher baseline ERK1/2 phosphorylation in the accompanying immunoblots. [1]
In a cell-based kynurenine screen at 1 μM, AZD8330 yielded reported kynurenine-production values of 16.0% in A172 cells and 80.7% in IFN-γ-stimulated A431 cells, with corresponding viability values of 103.0% and 112.4%. These screening results support a model-specific cellular effect; they do not establish direct TDO inhibition. [2]
Model-dependent osteosarcoma viability response
Cell-based study · Human osteosarcoma MOS, U2OS, 143b, KPD, ZK58 and Saos-2 cells in monolayer culture. [1]
AZD8330 reduced ATP-associated viability in MOS, U2OS and 143b after 72 hours. KPD, ZK58 and Saos-2 showed little response over the tested series. Results are relative to DMSO and do not establish activity in every osteosarcoma model.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response series plotted up to 1 μM (Figure 3A).
- Exposure duration
- 72 hours
- Method
- Single-agent exposure in monolayer culture; ATP-associated viability measured by luminescence.
- Vehicle
- DMSO comparator; final DMSO percentage not specified for this experiment.
- Reported limits
- Exact IC50 values are not tabulated for AZD8330 in Figure 3A; none estimated. The caption calls n three replicates without identifying them as independent biological experiments.
Methods and source locations
Compound reported in the paper: AZD8330; Compound label in the paper: AZD8330
Applies to the named AZD8330 research material in this paper; does not establish equivalence of an Adooq lot or an unreported formulation.
Figure 3A and caption; Results: MEK1/2 inhibition leads to apoptosis in cells with constitutive ERK activation; Methods: Cell viability and caspase3/7 activity
Cell viability after 72 hours, normalized to DMSO: ATPlite 1Step luminescence assay; Figure 3A reports mean ± s.e.m. of three replicates. — Figure 3A and caption; Results: MEK1/2 inhibition leads to apoptosis in cells with constitutive ERK activation; Methods: Cell viability and caspase3/7 activity
Suppression of ERK phosphorylation in responsive osteosarcoma cells
Cell-based study · Human osteosarcoma MOS, U2OS and 143b cells; baseline comparison also includes KPD, ZK58 and Saos-2. [1]
At 0.5 μM for 6 hours, AZD8330 reduced phospho-ERK1/2 bands in MOS, U2OS and 143b relative to DMSO. Total ERK1/2 and tubulin were assessed. Baseline phospho-ERK was prominent in the responsive lines and low in the three viability-insensitive lines.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5 μM
- Exposure duration
- 6 hours
- Method
- Single-agent treatment followed by immunoblotting.
- Vehicle
- DMSO control; final percentage not specified.
- Reported limits
- Figure 4 does not state the number of independent blots or provide quantitative phospho-ERK inhibition percentages.
Methods and source locations
Compound reported in the paper: AZD8330; Compound label in the paper: AZD8330
Applies to the named AZD8330 research material in this paper; does not establish equivalence of an Adooq lot or an unreported formulation.
Figure 4A–B and caption; same Results subsection; Methods: Reagents and antibodies, Immunoblotting
ERK1/2 phosphorylation after AZD8330 exposure: Western blot for phospho-ERK1/2, total ERK1/2 and tubulin; no quantitative densitometry reported in Figure 4. — Figure 4A–B and caption; same Results subsection; Methods: Reagents and antibodies, Immunoblotting
Kynurenine production and viability in a two-model screen
Cell-based study · TDO-expressing human A172 glioblastoma cells and IFN-γ-stimulated, IDO1-expressing human A431 cells. [2]
At the 1 μM screening concentration, Supplemental Table 2 reports much lower kynurenine production in A172 than in the A431 counter-screen, while viability values were preserved in both. These are cell-based screening endpoints and do not demonstrate direct TDO enzyme inhibition.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM (Supplemental Table 2 header; distinct from the 10 μM primary library screen).
- Exposure duration
- Shared cell-assay methods: compound pretreatment for 1 hour, followed by 24 hours after L-Trp addition.
- Method
- Kynurenine and WST-8 readouts in A172 and A431 counter-screen. Shared methods specify final L-Trp 524 μM for A172 and 178 μM for A431; A431 IDO1 stimulation uses IFN-γ 10 ng/mL.
- Vehicle
- Compounds dissolved in DMSO; final cell-assay DMSO percentage not stated.
- Co-treatment
- A431: IFN-γ stimulation, not an anticancer drug combination.
- Reported limits
- Table 2 does not separately identify replicate number, dispersion or the denominator used for its reported percentages. Shared Figure 1/Supplemental Figure 2 captions identify DMSO controls, but their n and error bars are not assigned to this table.
Methods and source locations
Compound reported in the paper: AZD8330; Compound label in the paper: AZD8330
Applies to the named AZD8330 research material in this paper; does not establish equivalence of an Adooq lot or an unreported formulation.
Supplemental Table 2 (AZD8330 row and Inhibitors (1 μM) header); main Results first subsection; Methods: Reagents and antibodies, Cell-based Kyn production assay, Cell viability assay
A172 kynurenine production in Supplemental Table 2: Cell-based Ehrlich-reaction assay. — Supplemental Table 2 (AZD8330 row and Inhibitors (1 μM) header); main Results first subsection; Methods: Reagents and antibodies, Cell-based Kyn production assay, Cell viability assay
A172 cell viability in Supplemental Table 2: WST-8 viability assay. — Supplemental Table 2 (AZD8330 row and Inhibitors (1 μM) header); main Results first subsection; Methods: Reagents and antibodies, Cell-based Kyn production assay, Cell viability assay
IFN-γ-stimulated A431 kynurenine production in Supplemental Table 2: Cell-based Ehrlich-reaction assay. — Supplemental Table 2 (AZD8330 row and Inhibitors (1 μM) header); main Results first subsection; Methods: Reagents and antibodies, Cell-based Kyn production assay, Cell viability assay
IFN-γ-stimulated A431 cell viability in Supplemental Table 2: WST-8 viability assay. — Supplemental Table 2 (AZD8330 row and Inhibitors (1 μM) header); main Results first subsection; Methods: Reagents and antibodies, Cell-based Kyn production assay, Cell viability assay
